StockNote
MED
Mediplantex Central Pharmaceutical Joint Stock Company (MED), formerly known as Nam - Bac Drug Company, was established in 1958. In 2005, it was transformed into Mediplantex Central Joint Stock Company (MED). Mediphantex's production and business activities are divided into three main segments, including: drug production, export, and import of drugs, of which revenue from distribution of imported drugs accounts for the largest proportion. Mediplantex's strongest products are medicinal products and antimalarial drug ingredients extracted from the golden flower plant. Mediplantex's drug import market is mainly from Korea. The company currently has 03 modern and closed drug factories and factories meeting GMP – who standards, supplying 6,000 - 8,000 million units of products/year; along with a storage system with an area of 10. 000 m2 meet GSP standards. On March 18, 2020, MED was officially traded on the Hanoi Stock Exchange (HNX).
MED currently has a market capitalization of roughly VND 228 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 10,5x is 69% below its own 7-year average (34,3x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 0,7x, 41% below its multi-year average of 1,1x. Return on equity (ROE) is at 6,6%, up from 4,8% the year before. Its debt-to-equity ratio of 0,1x is low, reflecting a conservative capital structure. In 2025, revenue fell 17% year-on-year while after-tax profit grew 4%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.